抑制劑溶液
Metabolism
GPCR/GProtein
Neuroscience
Apoptosis
Chromatin/Epigenetic
TyrosineKinase/Adaptors
Microbiology/Virology
Angiogenesis
CellCycle/Checkpoint
Membranetransporter/Ionchannel
Immunology/Inflammation
DNADamage/DNARepair
Autophagy
CytoskeletalSignaling
StemCells
PI3K/Akt/mTORsignaling
Proteases/Proteasome
MAPK
JAK/STATsignaling
Endocrinology/Hormones
Others
更多…
| 產(chǎn)品編號 | 圖片 | 產(chǎn)品描述 | 分子式 | 加入購物車 | |
|---|---|---|---|---|---|
|
TG101209，96% | C26H35N7O2S | |||
|
|
|||||
|
TG101348 (SAR302503)，98% | C27H36N6O3S | |||
|
|
|||||
|
Ibrutinib (PCI-32765)，99%(HPLC) | C25H24N6O2 | |||
|
|
|||||
|
ARRY-380，99% | C26H24N8O2 | |||
|
|
|||||
|
ARRY-380 (analog )，≥98% | C29H27N7O4S | |||
|
|
|||||
|
SB1317，≥98% | C23H24N4O | |||
|
|
|||||
|
Pacritinib，99% | C28H32N4O3 | |||
|
|
|||||
|
PF-00562271 besylate，98% | C21H20F3N7O3S·C6H6O3S | |||
|
|
|||||
|
NVP-BHG712，98% | C26H20F3N7O | |||
|
|
|||||
|
Ruxolitinib (INCB018424)，99% | C17H18N6 | |||
|
|
|||||
|
S-Ruxolitinib (INCB018424)，98% | C17H18N6 | |||
|
|
|||||
|
PF-03814735，99% | C23H25F3N6O2 | |||
|
|
|||||
|
GSK1070916，≥98% | C30H33N7O | |||
|
|
|||||
|
Ponatinib (AP24534)，98% | C29H27F3N6O | |||
|
|
|||||
|
Peficitinib，97% | C18H22N4O2 | |||
|
|
|||||
|
Decernotinib，98% | C18H19F3N6O | |||
|
|
|||||
|
XL019，98% | C25H28N6O2 | |||
|
|
|||||
|
TAK-593，98% | C23H23N7O3 | |||
|
|
|||||
|
KX2-391 (dihydrochloride)，98% | C26H31Cl2N3O3 | |||
|
|
|||||
|
Masitinib (mesylate)，99% | C29H34N6O4S2 | |||
|
|
|||||
